The terms “big data” and “forensic data analytics” (FDA) can seem daunting, especially to lawyers, who may feel more at home opining on legal issues than creating the charts, graphs and maps produced by FDA.  But analyzing big data this way provides a wealth of information that can be used to detect and prevent corruption and can go far in demonstrating a command of compliance to regulators and prosecutors.  Ernst & Young (EY) recently examined how companies use FDA in their “Global Forensic Data Analytics Survey 2014” (Survey).  Vincent Walden and Brian Loughman of EY’s Fraud Investigation & Dispute Services practice spoke with the Anti-Corruption Report about the significance of the Survey findings and how companies can use these tools.  EY’s Richard Sibery, with other FCPA experts, gave further insight into big data and FDA at a recent panel at the New York City Bar Association, “Using Data Analytics and Information Technology to Build and Manage an Effective Anti-Corruption Program.”  See also “Anti-Corruption Audits, Risk Assessments, Transaction Testing and the Dangers of Petty Cash: An Interview with Leaders of Ernst & Young’s Fraud Investigation & Dispute Services Practice” (Jun. 20, 2012).